National Tuberculosis AND Leprosy Pharmaceutical Import Profile — Nigeria (DGFT 2022–2026)

Name: National Tuberculosis AND Leprosy Pharmaceutical Import Records from India — 8 Products, $13.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

National Tuberculosis AND Leprosy — Pharmaceutical Importer Profile (2026) | 8 Products, $13.7M Trade | TransData Nexus

National Tuberculosis AND Leprosy

Pharmaceutical Importer · Nigeria · Tuberculosis Medications Focus · $13.7M Total Trade · DGFT Verified

National Tuberculosis AND Leprosy is a pharmaceutical importer based in Nigeria with a total trade value of $13.7M across 8 products in 3 therapeutic categories. Based on 273 verified import shipments from Indian Customs (DGFT) records, National Tuberculosis AND Leprosy is the #1 buyer in 4 products including Kit, Pyrazinamide, Linezolid. National Tuberculosis AND Leprosy sources from 6 verified Indian suppliers, with Lupin Limited accounting for 48.3% of imports.

National Tuberculosis AND Leprosy — Import Portfolio & Supplier Network

National Tuberculosis AND Leprosy import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to National Tuberculosis AND Leprosy?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lupin Limited	$3.4M	103	48.3%
Macleods Pharmaceuticals Limited	$2.0M	55	29.1%
Svizera Labs Private Limited

What Formulations Does National Tuberculosis AND Leprosy Import?

Formulation	Value	Ships
Stop tb cat i & iii patient kit a(gdf	$550.0K	11
Stop tb cat i & iii patient kit-a(gdf	$300.0K	6
12 strips of 28 tablets Each of rifampicin 150 MG/ isoniazid 75 MG tablets(6431x12)	$300.0K	6
6 strips of 28 tablets Each of rifampicin 150MG/isoniazid 75 MG/ pyrazinamide 400MG/ethambutol hcl 275MG tablets(6431x6)	$300.0K	6
Rifampicin 150MG+isoniazide 75MG+pyrazinamide 400MG+ethambutol 275MG)6x28tab+rifampicin 150MG+is(qty 5494 Box )	$292.1K	6
12 strips of 28 tablets Each of	$250.0K	5
6 strips of 28 tablets Each of	$250.0K	5
Rifa 75 & iso 50 TAB 3x28t gdf (pedia)	$250.0K	5
Tb kit cat i & iii kit a(stop tb kit)6	$250.0K	5
Stop tb cat i iii patient kit a gdf	$200.0K	4
Linezolid 600MG tablets. 10x10's	$200.0K	4
Pretomanid 200MG tablets (26's) ( dovprela ) (8,491.000 packs : 26's bottle	$150.0K	3
Stop tb cat i & iii patient kit-a (gdf)rifampicin 150MG+ isoniazide 75MG+ pyrazinamide 400MG+	$150.0K	3
Stop tb cat i & iii patient kit-a (gdf)rifampicin 150MG+ isoniazide 75MG+pyrazinamide 400MG+	$150.0K	3
Rifampicin 150MG+ isoniazide 75MG+ pyrazinamide 400MG+ ethambutol 275MG) 6x28tab + (rifampicin 150MG + isoniazid 75MG)	$146.0K	3

National Tuberculosis AND Leprosy imports 83 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Rifampicin	Advanced Antibiotics	$3.4M	67	0.2%	2
2	Isoniazid	Tuberculosis Medications	$3.1M	63	0.1%	2
3	Kit	Medical Devices & Diagnostics	$2.2M	44	0.4%	1
4	Ethambutol	Tuberculosis Medications	$1.9M	39	0.2%	2
5	Pyrazinamide	Tuberculosis Medications	$1.7M	34	0.2%	1
6	Strip	Medical Devices & Diagnostics	$1.1M	22	0.6%	9
7	Linezolid	Advanced Antibiotics	$100.0K	2	0.3%	1
8	Moxifloxacin	Advanced Antibiotics	$100.0K	2	0.3%	1

National Tuberculosis AND Leprosy imports 8 pharmaceutical products across 3 categories into Nigeria totaling $13.7M. The company is the #1 buyer for 4 products: Kit, Pyrazinamide, Linezolid, Moxifloxacin.

National Tuberculosis AND Leprosy — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The National Tuberculosis and Leprosy Control Programme (NTBLCP) is a division within Nigeria's Federal Ministry of Health, established in 1989 to coordinate efforts against tuberculosis (TB) and leprosy nationwide. Its mission is to reduce the prevalence of these diseases to the point where they no longer pose a public health risk in the country. (ntblcp.org.ng)

NTBLCP operates as a government agency, focusing on the procurement and distribution of essential medicines and medical supplies for TB and leprosy treatment. While it collaborates with various stakeholders, including international organizations and local health authorities, it does not have a parent company. Its role in Nigeria's pharmaceutical distribution is pivotal, ensuring the availability of necessary medications and diagnostics to combat these diseases effectively.

2Distribution Network

NTBLCP's distribution network spans all 774 Local Government Areas (LGAs) in Nigeria, integrating TB and leprosy services into the existing health system infrastructure. This extensive coverage ensures that diagnostic and treatment services are accessible to communities nationwide. (ntblcp.org.ng)

The program's logistics capabilities are designed to facilitate the timely delivery of medicines and medical supplies to health facilities across the country. By collaborating with public, private, and community health providers, NTBLCP aims to maintain a robust supply chain that supports the effective treatment and management of TB and leprosy cases.

3Industry Role

NTBLCP functions primarily as a government procurement agency, sourcing and distributing essential medicines and medical supplies for TB and leprosy treatment. Its role is central to Nigeria's pharmaceutical supply chain, ensuring that health facilities are equipped with the necessary resources to manage and treat these diseases effectively. (ntblcp.org.ng)

By coordinating with various stakeholders, including international organizations and local health authorities, NTBLCP plays a crucial role in the national response to TB and leprosy, contributing to the overall health infrastructure and disease control efforts in Nigeria.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — National Tuberculosis AND Leprosy

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

NTBLCP's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a select group of Indian suppliers. This concentrated sourcing approach suggests a strategic choice aimed at ensuring consistent quality and supply reliability.

The shipment data indicates a stable relationship with these suppliers, as evidenced by the consistent volume of imports over the years. However, this dependency also presents a potential risk; any disruption in the supply chain from these key suppliers could impact NTBLCP's ability to meet the national demand for TB and leprosy treatments.

2Supply Chain Resilience

NTBLCP's supply chain resilience is closely tied to the stability and reliability of its Indian suppliers. The program's focus on a limited number of suppliers may streamline procurement processes but also increases vulnerability to supply chain disruptions.

To enhance resilience, NTBLCP could consider diversifying its supplier base and establishing relationships with additional manufacturers. This strategy would mitigate risks associated with over-reliance on a few suppliers and ensure a more robust supply chain capable of withstanding potential disruptions.

Strategic Implications

Importing Pharmaceuticals into Nigeria — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Nigeria

1Regulatory Authority & Framework

The National Agency for Food and Drug Administration and Control (NAFDAC) is the primary regulatory body overseeing the manufacture, importation, exportation, advertisement, distribution, sale, and use of food, drugs, cosmetics, medical devices, chemicals, and packaged water in Nigeria.

Established in 1993, NAFDAC operates under the Federal Ministry of Health and is responsible for ensuring that all regulated products meet safety and efficacy standards. This includes the registration and approval of pharmaceutical products, monitoring of manufacturing practices, and enforcement of compliance with national and international regulations.

2Import Licensing & GMP

Importers of pharmaceutical products into Nigeria must obtain the necessary import licenses from NAFDAC, which involves submitting detailed documentation about the products, including their composition, manufacturing processes, and intended use. Additionally, NAFDAC requires that imported pharmaceutical products be manufactured in facilities that adhere to Good Manufacturing Practice (GMP) standards recognized by international bodies such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Importers must also secure wholesale distribution authorization from NAFDAC, which involves demonstrating compliance with regulatory requirements and maintaining appropriate storage and distribution facilities to ensure product integrity.

National Tuberculosis AND Leprosy — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

NTBLCP's focus on tuberculosis (TB) and leprosy medications aligns with the significant public health burden these diseases represent in Nigeria. By concentrating on these therapeutic areas, NTBLCP addresses critical health challenges and works towards reducing the prevalence of these diseases to the point where they no longer pose a public health risk. (ntblcp.org.ng)

The market demand for these imports is driven by the need for effective treatment options, diagnostic tools, and the necessity to combat drug-resistant strains of TB. NTBLCP's strategic procurement ensures that health facilities are equipped with the necessary resources to manage and treat these diseases effectively.

2Sourcing Profile

NTBLCP's sourcing strategy is centered on procuring generic drugs, primarily in finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. This approach ensures that the program can provide cost-effective treatments while maintaining quality standards.

India plays a significant role in NTBLCP's overall procurement strategy due to its capacity to produce high-quality generic medications at competitive prices. The program's focus on finished formulations from India allows for efficient procurement and distribution, ensuring timely availability of essential medicines for TB and leprosy treatment in Nigeria.

Market Positioning

Seller's Guide — How to Become a Supplier to National Tuberculosis AND Leprosy

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with NTBLCP, especially if they can offer high-quality generic medications that meet NAFDAC's regulatory standards. NTBLCP's concentrated sourcing pattern suggests that establishing relationships with the program could lead to significant procurement volumes.

Potential gaps in NTBLCP's current sourcing include the need for additional suppliers to enhance supply chain resilience and the potential for introducing new formulations or combination therapies to address emerging challenges in TB and leprosy treatment.

2Requirements & Qualifications

Indian exporters seeking to supply NTBLCP must ensure that their products are manufactured in facilities adhering to GMP standards recognized by international bodies such as WHO and PIC/S. Products must be registered with NAFDAC, which involves submitting detailed documentation about the products, including their composition, manufacturing processes, and intended use.

Additionally, exporters must comply with Nigeria's labeling requirements, ensuring that all information is in English and includes essential details such as the product name, active ingredients, dosage instructions, manufacturing and expiry dates, and storage conditions.

Frequently Asked Questions — National Tuberculosis AND Leprosy

What products does National Tuberculosis AND Leprosy import from India?

National Tuberculosis AND Leprosy imports 8 pharmaceutical products across 3 categories. Top imports: Rifampicin ($3.4M), Isoniazid ($3.1M), Kit ($2.2M), Ethambutol ($1.9M), Pyrazinamide ($1.7M).

Who supplies pharmaceuticals to National Tuberculosis AND Leprosy from India?

National Tuberculosis AND Leprosy sources from 6 verified Indian suppliers. The primary supplier is Lupin Limited (48.3% of imports, $3.4M).

What is National Tuberculosis AND Leprosy's total pharmaceutical import value?

National Tuberculosis AND Leprosy's total pharmaceutical import value from India is $13.7M, based on 273 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does National Tuberculosis AND Leprosy focus on?

National Tuberculosis AND Leprosy imports across 3 categories. The largest: Tuberculosis Medications (49.8%), Advanced Antibiotics (26.0%), Medical Devices & Diagnostics (24.2%).

Get Full National Tuberculosis AND Leprosy Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.